Arquitos Capital experienced a net return of -7.2% during the initial quarter of 2026, a period in which the Russell 2000 index posted a 0.9% increase. The firm's investment approach zeroes in on niche opportunities, specifically targeting pre-revenue biotechnology firms that trade considerably below their cash reserves following unsuccessful Phase 3 clinical trials. This strategy aligns with the firm's historical success in identifying mispriced assets during market dislocations.

Arquitos Capital's strategy is rooted in the observation that distinct investor cohorts react differently to corporate events. When a biotech company's drug fails a Phase 3 trial, its initial investor base, typically focused on drug development, tends to divest shares without considering the company's underlying cash position or tax assets. This indiscriminate selling creates opportunities for value investors to acquire shares at a discount to net cash. The firm actively seeks out companies where management can be influenced to implement economically rational decisions, such as workforce reductions, lease terminations, intellectual property assessment, and the return of capital to shareholders, potentially followed by the sale of the corporate shell and its tax loss carryforwards.

ENDI Corp. (ENDI), a notable holding, recorded a decrease from $16.75 to $15.00 per share during the first quarter of 2026. However, the company demonstrated robust performance in 2025, with assets under management escalating by 21% to $4.1 billion, and overall revenue climbing 38% to $21.3 million. Adjusted EBITDA also saw a significant rise to $11.1 million, and the company concluded 2025 with $53 million in cash and investments, a substantial increase from the prior year.

Finch Therapeutics (FNCH) shares experienced a decline from $13.49 to $9.64. Despite this, the inherent value of the company remains intact. Finch has strategically filed for Chapter 11 to mitigate lease obligations and facilitate an outright sale. This sale encompasses a patent infringement litigation claim against Ferring Pharmaceuticals, a portfolio of 160 issued patents, a potential additional infringement case, and valuable net operating loss carryforwards. This calculated move is anticipated to maximize shareholder value by monetizing assets more effectively than if the company continued as a public entity.

Liquidia Corporation (LQDA) witnessed an increase in share price from $34.49 to $37.74. The company's Yutrepia product launch has been exceptionally successful. The imminent judicial decision regarding Liquidia's patent infringement case with United Therapeutics (UTHR) is a significant near-term catalyst. Projections indicate that if Liquidia prevails, shares could reach $140 per share. Even in scenarios involving a 10% royalty or, less likely, a permanent injunction on certain sales, the shares are estimated to be worth approximately $123 and $70 respectively by 2027. The company's growth potential extends beyond 2027, with a capacity to capture a substantial portion of the treprostinil market and expand the total addressable market.

Arquitos Capital remains committed to identifying and capitalizing on undervalued investment opportunities, particularly within the biotechnology and biopharmaceutical sectors. The firm’s focus on companies undergoing significant corporate changes or facing mispricing due to shifting investor interests continues to be a cornerstone of its strategy. Investors are encouraged to review their individual statements for specific performance details and to consider the long-term compounding potential of these unique investments.